Rigel Pharmaceuticals RIGL Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's operating income?
- Rigel Pharmaceuticals (RIGL) reported operating income of $11.89M in Q1 2026.
- How has Rigel Pharmaceuticals's operating income changed year-over-year?
- Rigel Pharmaceuticals's operating income decreased by 7.0% year-over-year, from $12.77M to $11.89M.
- What is the long-term trend for Rigel Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's operating income has grown at a 78.0% compound annual growth rate (CAGR), from -$12.5M to $125.47M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.